Payment overview · 2025
General Payments
$114.09
6 reported records · 5 companies
Healthcare provider profile · identity verified
Denise Workman, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLEVELAND, GA · NPI 1780625293
Verified facts
What the public records show
CMS Open Payments records show Denise Workman, D.O. received $114.09 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.67 | 39.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.74 | 18.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.47 | 14.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.22 | 14.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 14.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $98.10 | 5 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 515 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 73 |
| Lisinopril | Lisinopril | 313 | 79 |
| Gabapentin | Gabapentin | 294 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 259 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 56 |
| Metformin Hcl | Metformin Hcl | 226 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 216 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 54 |
| Omeprazole | Omeprazole | 200 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 49 |
| Losartan Potassium | Losartan Potassium | 179 | 49 |
| Potassium Chloride | Potassium Chloride | 174 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 36 |
| Montelukast Sodium | Montelukast Sodium | 154 | 27 |
| Famotidine | Famotidine | 153 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 34 |
| Trazodone Hcl | Trazodone Hcl | 145 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 29 |
| Furosemide | Furosemide | 133 | 32 |
| Eliquis | Apixaban | 131 | 26 |
| Buspirone Hcl | Buspirone Hcl | 127 | 23 |
| Sertraline Hcl | Sertraline Hcl | 125 | 27 |
| Alprazolam | Alprazolam | 123 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 37 |
| Mounjaro | Tirzepatide | 116 | 21 |
| Ozempic | Semaglutide | 108 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 26 |
| Simvastatin | Simvastatin | 105 | 26 |
| Tramadol Hcl | Tramadol Hcl | 97 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 14 |
| Prednisone | Prednisone | 83 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 18 |
| Lovastatin | Lovastatin | 82 | 20 |
| Bupropion Xl | Bupropion Hcl | 77 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 17 |
| Topiramate | Topiramate | 71 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 18 |
| Celecoxib | Celecoxib | 67 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 11 |
| Pregabalin | Pregabalin | 67 | 12 |
| Trulicity | Dulaglutide | 65 | 18 |
| Ezetimibe | Ezetimibe | 63 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 11 |
| Glipizide Er | Glipizide | 62 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 11 |
| Repatha Sureclick | Evolocumab | 61 | suppressed |
| Buprenorphine | Buprenorphine | 60 | suppressed |
| Meloxicam | Meloxicam | 59 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 11 |
| Colchicine | Colchicine | 51 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 17 |
| Methadone Hcl | Methadone Hcl | 50 | suppressed |
| Aripiprazole | Aripiprazole | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | suppressed |
| Finasteride | Finasteride | 48 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Fluconazole | Fluconazole | 46 | 20 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 21 |
| Estradiol | Estradiol | 43 | suppressed |
| Movantik | Naloxegol Oxalate | 43 | suppressed |
| Glipizide | Glipizide | 42 | 12 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Xtampza Er | Oxycodone Myristate | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 27 |
| Lidocaine | Lidocaine | 35 | 11 |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Belbuca | Buprenorphine Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 15 |
| Atenolol | Atenolol | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Constulose | Lactulose | 23 | suppressed |
| Prolia | Denosumab | 23 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Carvedilol | Carvedilol | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Roxicodone | Oxycodone Hcl | 12 | suppressed |
| Soma | Carisoprodol | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $114.09 · 6 records | ABBVIE INC. | BREZTRI, CAPLYTA, FANAPT, MOUNJARO, UBRELVY, VRAYLAR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error